Search

Your search keyword '"Tagliaferri, Mary A."' showing total 222 results
Start Over Author "Tagliaferri, Mary A."
222 results on '"Tagliaferri, Mary A."'

1. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials

Author

Silverberg, Jonathan I., Rosmarin, David, Chovatiya, Raj, Bieber, Thomas, Schleicher, Stephen, Beck, Lisa, Gooderham, Melinda, Chaudhry, Sohail, Fanton, Christie, Yu, Danni, Levy, Joshua, Liu, Yi, Miyazaki, Takahiro, Tagliaferri, Mary, Schmitz, Carsten, Nirula, Ajay, Kotzin, Brian, and Zalevsky, Jonathan

Published
2024
Full Text
View/download PDF

2. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Author

Srinagesh, Hrishikesh, Jackson, Clayton, Shiraz, Parveen, Jeyakumar, Nikeshan, Hamilton, Mark, Egeler, Emily, Mavroukakis, Sharon, Kuo, Adam, Cancilla, Juancarlos, Sahaf, Bita, Agarwal, Neha, Kanegai, Alyssa, Kramer, Anne Marijn, Arai, Sally, Bharadwaj, Sushma, Dahiya, Saurabh, Hosoya, Hitomi, Johnston, Laura, Kennedy, Vanessa, Liedtke, Michaela, Lowsky, Robert, Mikkilineni, Lekha, Negrin, Robert, Rezvani, Andrew, Sidana, Surbhi, Shizuru, Judith, Smith, Melody, Weng, Wen-Kai, Feldman, Steven, Frank, Matthew J., Lee, Zachary, Tagliaferri, Mary, Marcondes, A. Mario, Miklos, David, Mackall, Crystal, and Muffly, Lori

Published
2024
Full Text
View/download PDF

3. ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

Author

Tripathy, Debu, Tolaney, Sara M, Seidman, Andrew D, Anders, Carey K, Ibrahim, Nuhad, Rugo, Hope S, Twelves, Chris, Dieras, Veronique, Müller, Volkmar, Tagliaferri, Mary, Hannah, Alison L, and Cortés, Javier

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Neurosciences, Clinical Trials and Supportive Activities, Breast Cancer, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Brain Neoplasms, Breast Neoplasms, Female, Heterocyclic Compounds, 4 or More Rings, Humans, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Polyethylene Glycols, Progression-Free Survival, Topoisomerase I Inhibitors, brain metastases, chemotherapy, etirinotecan pegol, metastatic breast cancer, NKTR-102, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels. Motivated by improved survival findings from subgroup analyses from the Phase III BEACON trial, this ongoing randomized, Phase III trial compares etirinotecan pegol to drugs commonly used for advanced breast cancer in patients with stable, treated breast cancer brain metastases who have been previously treated with an anthracycline, taxane and capecitabine. The primary end point is overall survival. Secondary end points include objective response rate, progression-free survival and time to CNS disease progression or recurrence in patients with/without CNS lesions present at study entry. Trial registration number: NCT02915744.

Published
2019

5. Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)

Author

Tannir, Nizar M., primary, Formiga, Maria Nirvana, additional, Penkov, Konstantin, additional, Kislov, Nikolay, additional, Vasiliev, Aleksandr, additional, Gunnar Skare, Nils, additional, Hong, Walter, additional, Dai, Stanley, additional, Tang, Lily, additional, Qureshi, Anila, additional, Zalevsky, Jonathan, additional, Tagliaferri, Mary A., additional, George, Daniel, additional, Agarwal, Neeraj, additional, and Pal, Sumanta, additional

Published
2024
Full Text
View/download PDF

6. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Author

Cortés, Javier, Rugo, Hope S, Awada, Ahmad, Twelves, Chris, Perez, Edith A, Im, Seock–Ah, Gómez-Pardo, Patricia, Schwartzberg, Lee S, Diéras, Veronique, Yardley, Denise A, Potter, David A, Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L, and O’Shaughnessy, Joyce

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Cancer, Neurosciences, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Brain metastases, Etirinotecan pegol, NKTR-102, Chemotherapy, Metastatic breast cancer, Clinical Sciences, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeConventional chemotherapy has limited activity in patients with breast cancer and brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 inhibitor, was designed using advanced polymer technology to preferentially accumulate in tumor tissue including brain metastases, providing sustained cytotoxic SN38 levels.MethodsThe phase 3 BEACON trial enrolled 852 women with heavily pretreated locally recurrent or metastatic breast cancer between 2011 and 2013. BEACON compared EP with treatment of physician's choice (TPC; eribulin, vinorelbine, gemcitabine, nab-paclitaxel, paclitaxel, ixabepilone, or docetaxel) in patients previously treated with anthracycline, taxane, and capecitabine, including those with treated, stable brain metastases. The primary endpoint, overall survival (OS), was assessed in a pre-defined subgroup of BCBM patients; an exploratory post hoc analysis adjusting for the diagnosis-specific graded prognostic assessment (GPA) index was also conducted.ResultsIn the trial, 67 BCBM patients were randomized (EP, n = 36; TPC, n = 31). Treatment subgroups were balanced for baseline characteristics and GPA indices. EP was associated with a significant reduction in the risk of death (HR 0.51; P

Published
2017

7. Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial

Author

Cortés, Javier, Rugo, Hope S, Twelves, Chris, Awada, Ahmad, Perez, Edith A, Im, Seock-Ah, Zhao, Carol, Hoch, Ute, Tomkinson, Denise, Buchanan, James, Tagliaferri, Mary, Hannah, Alison, and O’Shaughnessy, Joyce

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Patient Safety, Clinical Trials and Supportive Activities, Clinical Research, Vaccine Related, Cancer, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Etirinotecan pegol, Metastatic breast cancer, Chemotherapy safety, Chemotherapy side effects
Abstract

PurposeNew treatments with novel mechanisms of action and non-overlapping toxicities are needed for patients with metastatic breast cancer. Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor with a unique toxicity profile. The randomized phase 3 BEACON study that compared EP to treatment of physician's choice (TPC) demonstrated its clinical activity. We now present detailed safety data from the BEACON trial.MethodsPatients with locally recurrent or metastatic breast cancer who had received at least two prior cytotoxic regimens for advanced disease were randomized to EP or TPC. Prior treatment with an anthracycline, a taxane and capecitabine was required. The frequencies of treatment-emergent AEs (TEAEs) and serious TEAEs were evaluated for the safety population, comprising all patients who received at least one dose of assigned treatment.ResultsA total of 831 patients were evaluated (n = 425, EP; n = 406, TPC). Compared with TPC, EP was associated with a slightly higher median relative dose intensity (98.3 vs. 92.8 %, respectively) and significantly fewer grade ≥3 toxicities (48.0 vs. 63.1 %, P

Published
2016

8. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

Author

Diab, Adi, primary, Gogas, Helen, additional, Sandhu, Shahneen, additional, Long, Georgina V., additional, Ascierto, Paolo A., additional, Larkin, James, additional, Sznol, Mario, additional, Franke, Fabio, additional, Ciuleanu, Tudor E., additional, Pereira, Caio, additional, Muñoz Couselo, Eva, additional, Bronzon Damian, Fernanda, additional, Schenker, Michael, additional, Perfetti, Aldo, additional, Lebbe, Celeste, additional, Quéreux, Gaëlle, additional, Meier, Friedegund, additional, Curti, Brendan D., additional, Rojas, Carlos, additional, Arriaga, Yull, additional, Yang, Haisu, additional, Zhou, Ming, additional, Ravimohan, Shruthi, additional, Statkevich, Paul, additional, Tagliaferri, Mary A., additional, and Khushalani, Nikhil I., additional

Published
2023
Full Text
View/download PDF

9. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial

Author

Twelves, Chris, Cortés, Javier, O'Shaughnessy, Joyce, Awada, Ahmad, Perez, Edith A., Im, Seock–Ah, Gómez-Pardo, Patricia, Schwartzberg, Lee S., Diéras, Véronique, Yardley, Denise A., Potter, David A., Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L., and Rugo, Hope S.

Published
2017
Full Text
View/download PDF

10. Supplementary Appendix from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Author

Diab, Adi, primary, Tannir, Nizar M., primary, Bentebibel, Salah-Eddine, primary, Hwu, Patrick, primary, Papadimitrakopoulou, Vassiliki, primary, Haymaker, Cara, primary, Kluger, Harriet M., primary, Gettinger, Scott N., primary, Sznol, Mario, primary, Tykodi, Scott S., primary, Curti, Brendan D., primary, Tagliaferri, Mary A., primary, Zalevsky, Jonathan, primary, Hannah, Alison L., primary, Hoch, Ute, primary, Aung, Sandra, primary, Fanton, Christie, primary, Rizwan, Ahsan, primary, Iacucci, Ernesto, primary, Liao, Yijie, primary, Bernatchez, Chantale, primary, Hurwitz, Michael E., primary, and Cho, Daniel C., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Data from A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Author

Bentebibel, Salah-Eddine, primary, Hurwitz, Michael E., primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Hudgens, Courtney W., primary, Kluger, Harriet M., primary, Tetzlaff, Michael T., primary, Tagliaferri, Mary A., primary, Zalevsky, Jonathan, primary, Hoch, Ute, primary, Fanton, Christie, primary, Aung, Sandra, primary, Hwu, Patrick, primary, Curti, Brendan D., primary, Tannir, Nizar M., primary, Sznol, Mario, primary, and Diab, Adi, primary

Published
2023
Full Text
View/download PDF

12. CD-19-1510R1_Supplementary_Appendix.docx from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Author

Diab, Adi, primary, Tannir, Nizar M., primary, Bentebibel, Salah-Eddine, primary, Hwu, Patrick, primary, Papadimitrakopoulou, Vassiliki, primary, Haymaker, Cara, primary, Kluger, Harriet M., primary, Gettinger, Scott N., primary, Sznol, Mario, primary, Tykodi, Scott S., primary, Curti, Brendan D., primary, Tagliaferri, Mary A., primary, Zalevsky, Jonathan, primary, Hannah, Alison L., primary, Hoch, Ute, primary, Aung, Sandra, primary, Fanton, Christie, primary, Rizwan, Ahsan, primary, Iacucci, Ernesto, primary, Liao, Yijie, primary, Bernatchez, Chantale, primary, Hurwitz, Michael E., primary, and Cho, Daniel C., primary

Published
2023
Full Text
View/download PDF

13. Data from A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Author

Bentebibel, Salah-Eddine, primary, Hurwitz, Michael E., primary, Bernatchez, Chantale, primary, Haymaker, Cara, primary, Hudgens, Courtney W., primary, Kluger, Harriet M., primary, Tetzlaff, Michael T., primary, Tagliaferri, Mary A., primary, Zalevsky, Jonathan, primary, Hoch, Ute, primary, Fanton, Christie, primary, Aung, Sandra, primary, Hwu, Patrick, primary, Curti, Brendan D., primary, Tannir, Nizar M., primary, Sznol, Mario, primary, and Diab, Adi, primary

Published
2023
Full Text
View/download PDF

14. Data from Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Author

Diab, Adi, primary, Tannir, Nizar M., primary, Bentebibel, Salah-Eddine, primary, Hwu, Patrick, primary, Papadimitrakopoulou, Vassiliki, primary, Haymaker, Cara, primary, Kluger, Harriet M., primary, Gettinger, Scott N., primary, Sznol, Mario, primary, Tykodi, Scott S., primary, Curti, Brendan D., primary, Tagliaferri, Mary A., primary, Zalevsky, Jonathan, primary, Hannah, Alison L., primary, Hoch, Ute, primary, Aung, Sandra, primary, Fanton, Christie, primary, Rizwan, Ahsan, primary, Iacucci, Ernesto, primary, Liao, Yijie, primary, Bernatchez, Chantale, primary, Hurwitz, Michael E., primary, and Cho, Daniel C., primary

Published
2023
Full Text
View/download PDF

15. Supplemental Tables and Figures from Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

Author

Rugo, Hope S., primary, Cortes, Javier, primary, Awada, Ahmad, primary, O'Shaughnessy, Joyce, primary, Twelves, Chris, primary, Im, Seock-Ah, primary, Hannah, Alison, primary, Lu, Lin, primary, Sy, Sherwin, primary, Caygill, Katie, primary, Zajchowski, Deborah A., primary, Davis, Darren W., primary, Tagliaferri, Mary, primary, Hoch, Ute, primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

16. Early Results of a Phase I Study of CAR-T Cells + NKTR-255 (PEG-IL-15) in Adults with R/R ALL

Author

Jackson, Clayton, primary, Shiraz, Parveen, additional, Iglesias, Maria, additional, Egeler, Emily, additional, Sahaf, Bita, additional, Arai, Sally, additional, Bharadwaj, Sushma, additional, Johnston, Laura, additional, Lowsky, Robert, additional, Meyer, Everett H., additional, Negrin, Robert S., additional, Rezvani, Andrew R., additional, Weng, Wen-Kai, additional, Shizuru, Judith A., additional, Marcondes, Mario Q., additional, Tagliaferri, Mary A., additional, Sidana, Surbhi, additional, Frank, Matthew J., additional, Smith, Melody, additional, Feldman, Steven, additional, Miklos, David B., additional, Mackall, Crystal, additional, Syal, Shriya, additional, Patil, Sunita, additional, Reynolds, Warren D., additional, and Muffly, Lori, additional

Published
2023
Full Text
View/download PDF

17. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

Author

Perez, Edith A, Awada, Ahmad, O'Shaughnessy, Joyce, Rugo, Hope S, Twelves, Chris, Im, Seock-Ah, Gómez-Pardo, Patricia, Schwartzberg, Lee S, Diéras, Veronique, Yardley, Denise A, Potter, David A, Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L, and Cortes, Javier

Published
2015
Full Text
View/download PDF

19. A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Author

Perales, Miguel-Angel, primary, Ahmed, Sairah, additional, Dahiya, Saurabh, additional, Riedell, Peter A., additional, McGuirk, Joseph P., additional, Oluwole, Olalekan O., additional, Chaudhry, Sohail A., additional, Lee, Zachary, additional, Dai, Stanley, additional, Dixit, Neha, additional, Fanton, Christie, additional, Marcondes, Mario Q., additional, Zalevsky, Jonathan, additional, Tagliaferri, Mary A., additional, and Turtle, Cameron J., additional

Published
2022
Full Text
View/download PDF

20. Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Author

Patel, Krina, primary, Shah, Nina, additional, Tan, Alan, additional, Cowan, Andrew J, additional, Turtle, Cameron J., additional, Hofmeister, Craig C, additional, Choi, Taewoong, additional, Saeed, Hayder, additional, Chavez, Julio C., additional, Pianko, Matthew J., additional, Gandhi, Mitul, additional, Chaudhry, Sohail A., additional, Lee, Zachary, additional, Dixit, Neha, additional, Fanton, Christie, additional, Wang, Xiaoli, additional, Xu, Heng, additional, Marcondes, Mario Q., additional, Tagliaferri, Mary A., additional, Zalevsky, Jonathan, additional, and Perales, Miguel-Angel, additional

Published
2022
Full Text
View/download PDF

22. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

Author

Eggermont, Alexander Mm, Ascierto, Paolo A., Khushalani, Nikhil I., Schadendorf, Dirk, Boland, Genevieve, Weber, Jeffrey, Lewis, Karl D., Johnson, Daniel, Rivalland, Gareth, Khattak, Adnan, Majem, Margarita, Gogas, Helen, Long, Georgina V., Currie, Sue L., Chien, David, Tagliaferri, Mary A., Carlino, Matteo S., Diab, Adi, Eggermont, Alexander Mm, Ascierto, Paolo A., Khushalani, Nikhil I., Schadendorf, Dirk, Boland, Genevieve, Weber, Jeffrey, Lewis, Karl D., Johnson, Daniel, Rivalland, Gareth, Khattak, Adnan, Majem, Margarita, Gogas, Helen, Long, Georgina V., Currie, Sue L., Chien, David, Tagliaferri, Mary A., Carlino, Matteo S., and Diab, Adi

Abstract

Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. PIVOT-02 showed that BEMPEG plus NIVO was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma. PIVOT-12 is a randomized, phase III, global, multicenter, open-label study comparing adjuvant therapy with BEMPEG plus NIVO versus NIVO alone in adult and adolescent patients with completely resected cutaneous stage III/IV melanoma at high risk of recurrence. The primary objective is to compare the efficacy, as measured by recurrence-free survival, of BEMPEG plus NIVO versus NIVO.

Published
2022

23. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

Author

Tannir, Nizar M, primary, Cho, Daniel C, additional, Diab, Adi, additional, Sznol, Mario, additional, Bilen, Mehmet A, additional, Balar, Arjun V, additional, Grignani, Giovanni, additional, Puente, Erika, additional, Tang, Lily, additional, Chien, David, additional, Hoch, Ute, additional, Choudhury, Arkopal, additional, Yu, Danni, additional, Currie, Sue L, additional, Tagliaferri, Mary A, additional, Zalevsky, Jonathan, additional, Siefker-Radtke, Arlene O, additional, and Hurwitz, Michael E, additional

Published
2022
Full Text
View/download PDF

24. PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

Author

Eggermont, Alexander M. M. Ascierto, Paolo A. Khushalani, I, Nikhil Schadendorf, Dirk Boland, Genevieve Weber, Jeffrey and Lewis, Karl D. Johnson, Daniel Rivalland, Gareth and Khattak, Adnan Majem, Margarita Gogas, Helen Long, V, Georgina Currie, Sue L. Chien, David Tagliaferri, Mary A. and Carlino, Matteo S. Diab, Adi

Abstract

Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-L1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. PIVOT-02 showed that BEMPEG plus NIVO was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma. PIVOT-12 is a randomized, Phase Ill, global, multicenter, open-label study comparing adjuvant therapy with BEMPEG plus NIVO versus NIVO alone in adult and adolescent patients with completely resected cutaneous stage III/IV melanoma at high risk of recurrence. The primary objective is to compare the efficacy, as measured by recurrence-free survival, of BEMPEG plus NIVO versus NIVO. Lay abstract: Following surgery, patients with advanced melanoma may require further treatment to reduce the likelihood of disease recurrence. Nivolumab (NIVO), a checkpoint inhibitor, reduces the risk of melanoma recurrence by enhancing the ability of the immune system to fight disease. Despite the availability of NIVO and other therapies, many patients with melanoma still experience disease recurrence after surgery. This article presents information on a clinical trial named PIVOT-12, which aims to assess the effectiveness of a new investigational drug called bempegaldesleukin that modifies the immune system and is given with NIVO to patients with stage III/IV melanoma following surgery. The main end point being measured is recurrence-free survival, which measures the time between a patient starting the study and the date of disease recurrence.

Published
2022

25. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

Author

Eggermont, Alexander MM, primary, Ascierto, Paolo A, additional, Khushalani, Nikhil I, additional, Schadendorf, Dirk, additional, Boland, Genevieve, additional, Weber, Jeffrey, additional, Lewis, Karl D, additional, Johnson, Daniel, additional, Rivalland, Gareth, additional, Khattak, Adnan, additional, Majem, Margarita, additional, Gogas, Helen, additional, Long, Georgina V, additional, Currie, Sue L, additional, Chien, David, additional, Tagliaferri, Mary A, additional, Carlino, Matteo S, additional, and Diab, Adi, additional

Published
2022
Full Text
View/download PDF

28. Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Author

Shah, Nina, primary, Tan, Alan, additional, Budde, Elizabeth, additional, Hofmeister, Craig C., additional, Cowan, Andrew J., additional, Perales, Miguel-Angel, additional, Choi, Taewoong, additional, Saeed, Hayder, additional, Chavez, Julio C., additional, Ye, Jing C., additional, Cairo, Mitchell S., additional, Rizzieri, David A., additional, Orloff, Gregory J., additional, Lee, Zachary, additional, Dixit, Neha, additional, Nieves, Wildaliz, additional, Zhao, Qiang, additional, Wang, Xiaoli, additional, Kai, Kazuharu, additional, Marcondes, Mario Q., additional, Tagliaferri, Mary A., additional, Zalevsky, Jonathan, additional, and Patel, Krina K., additional

Published
2021
Full Text
View/download PDF

29. 957 NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study

Author

Altan, Mehmet, primary, Patnaik, Amita, additional, Barve, Minal, additional, Dunn, Lara, additional, Cobb, Patrick, additional, Rosenberg, Ari, additional, Sharma, Sunil, additional, Sukari, Ammar, additional, Patel, Manish, additional, Wang, Xiaoli, additional, Ma, Haijun, additional, Dixit, Neha, additional, Nieves, Wildaliz, additional, Fanton, Christie, additional, Currie, Sue, additional, Lee, Zachary, additional, Marcondes, Mario, additional, Zalevsky, Johnathan, additional, Tagliaferri, Mary, additional, and Sacco, Assuntina, additional

Published
2021
Full Text
View/download PDF

30. Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Author

Cortés, Javier, Rugo, Hope S., Awada, Ahmad, Twelves, Chris, Perez, Edith A., Im, Seock–Ah, Gómez-Pardo, Patricia, Schwartzberg, Lee S., Diéras, Veronique, Yardley, Denise A., Potter, David A., Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L., and O’Shaughnessy, Joyce

Published
2017
Full Text
View/download PDF

32. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Author

Diab, Adi, primary, Tykodi, Scott S., additional, Daniels, Gregory A., additional, Maio, Michele, additional, Curti, Brendan D., additional, Lewis, Karl D., additional, Jang, Sekwon, additional, Kalinka, Ewa, additional, Puzanov, Igor, additional, Spira, Alexander I., additional, Cho, Daniel C., additional, Guan, Shanhong, additional, Puente, Erika, additional, Nguyen, Tuan, additional, Hoch, Ute, additional, Currie, Sue L., additional, Lin, Wei, additional, Tagliaferri, Mary A., additional, Zalevsky, Jonathan, additional, Sznol, Mario, additional, and Hurwitz, Michael E., additional

Published
2021
Full Text
View/download PDF

33. Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies

Author

Shah, Nina, primary, Perales, Miguel-Angel, additional, Turtle, Cameron J, additional, Cairo, Mitchell S, additional, Cowan, Andrew J, additional, Saeed, Hayder, additional, Budde, Lihua E, additional, Tan, Alan, additional, Lee, Zachary, additional, Kai, Kazuharu, additional, Marcondes, Mario Q, additional, Zalevsky, Jonathan, additional, Tagliaferri, Mary A, additional, and Patel, Krina K, additional

Published
2021
Full Text
View/download PDF

40. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer

Author

Huddart, Robert A, primary, Siefker-Radtke, Arlene O, additional, Balar, Arjun V, additional, Bilen, Mehmet A, additional, Powles, Thomas, additional, Bamias, Aristotelis, additional, Castellano, Daniel, additional, Khalil, Maged F, additional, Van Der Heijden, Michiel S, additional, Koshkin, Vadim S, additional, Pook, David W, additional, Özgüroğlu, Mustafa, additional, Santiago, Linda, additional, Zhong, Bob, additional, Chien, David, additional, Lin, Wei, additional, Tagliaferri, Mary A, additional, and Loriot, Yohann, additional

Published
2021
Full Text
View/download PDF

42. 274 - Early Results of a Phase I Study of CAR-T Cells + NKTR-255 (PEG-IL-15) in Adults with R/R ALL

Author

Jackson, Clayton, Shiraz, Parveen, Iglesias, Maria, Egeler, Emily, Sahaf, Bita, Arai, Sally, Bharadwaj, Sushma, Johnston, Laura, Lowsky, Robert, Meyer, Everett H., Negrin, Robert S., Rezvani, Andrew R., Weng, Wen-Kai, Shizuru, Judith A., Marcondes, Mario Q., Tagliaferri, Mary A., Sidana, Surbhi, Frank, Matthew J., Smith, Melody, Feldman, Steven, Miklos, David B., Mackall, Crystal, Syal, Shriya, Patil, Sunita, Reynolds, Warren D., and Muffly, Lori

Published
2023
Full Text
View/download PDF

44. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

Author

Diab, Adi, primary, Tykodi, Scott, additional, Daniels, Gregory, additional, Maio, Michele, additional, Curti, Brendan, additional, Lewis, Karl, additional, Jang, Sekwon, additional, Kalinka, Ewa, additional, Puzanov, Igor, additional, Spira, Alexander, additional, Cho, Daniel, additional, Guan, Shanhong, additional, Puente, Erika, additional, Hoch, Ute, additional, Currie, Sue, additional, Nguyen, Tuan, additional, Lin, Wei, additional, Tagliaferri, Mary, additional, Zalevsky, Jonathan, additional, Sznol, Mario, additional, and Hurwitz, Michael, additional

Published
2020
Full Text
View/download PDF

45. 355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies

Author

Shah, Nina, primary, Tan, Alan, additional, Budde, Lihua, additional, Hofmeister, Craig, additional, Cowan, Andrew, additional, Saeed, Hayder, additional, Ye, Jing, additional, Cairo, Mitchell, additional, Rizzieri, David, additional, Orloff, Gregory, additional, Ge, Xue Snow, additional, Lee, Zachary, additional, Dixit, Neha, additional, Nieves, Wildaliz, additional, Vimal, Mona, additional, Ma, Haijun, additional, Miyazaki, Takahiro, additional, Madakamutil, Loui, additional, Marcondes, Mario, additional, Lin, Wei, additional, Tagliaferri, Mary, additional, Zalevsky, Jonathan, additional, and Patel, Krina, additional

Published
2020
Full Text
View/download PDF

46. 368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

Author

Diab, Adi, primary, Curti, Brendan, additional, Bilen, Mehmet, additional, Brohl, Andrew, additional, Domingo-Musibay, Evidio, additional, Borazanci, Erkut, additional, Fanton, Christie, additional, Haglund, Cat, additional, Vimal, Mona, additional, Muhsin, Mann, additional, Marcondes, Mario, additional, Nguyen, Anh, additional, Tagliaferri, Mary, additional, Lin, Wei, additional, Zalevsky, Jonathan, additional, and D’Angelo, Sandra, additional

Published
2020
Full Text
View/download PDF

47. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Author

Diab, Adi, primary, Tannir, Nizar M., additional, Bentebibel, Salah-Eddine, additional, Hwu, Patrick, additional, Papadimitrakopoulou, Vassiliki, additional, Haymaker, Cara, additional, Kluger, Harriet M., additional, Gettinger, Scott N., additional, Sznol, Mario, additional, Tykodi, Scott S., additional, Curti, Brendan D., additional, Tagliaferri, Mary A., additional, Zalevsky, Jonathan, additional, Hannah, Alison L., additional, Hoch, Ute, additional, Aung, Sandra, additional, Fanton, Christie, additional, Rizwan, Ahsan, additional, Iacucci, Ernesto, additional, Liao, Yijie, additional, Bernatchez, Chantale, additional, Hurwitz, Michael E., additional, and Cho, Daniel C., additional

Published
2020
Full Text
View/download PDF

48. Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain

Author

Henningfield, Jack E, primary, Gudin, Jeffrey, additional, Rauck, Richard, additional, Gimbel, Joseph, additional, Tagliaferri, Mary, additional, Doberstein, Stephen K, additional, Di Fonzo, Carlo, additional, Lu, Lin, additional, Katz, Nathaniel, additional, Siddhanti, Suresh, additional, and Schnoll, Sidney, additional

Published
2020
Full Text
View/download PDF

49. PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).

Author

Huddart, Robert A., primary, Siefker-Radtke, Arlene O., additional, Balar, Arjun Vasant, additional, Bilen, Mehmet Asim, additional, Powles, Thomas, additional, Bamias, Aristotelis, additional, Castellano, Daniel, additional, Khalil, Maged F., additional, Van Der Heijden, Michiel Simon, additional, Koshkin, Vadim S, additional, Pook, David William, additional, Ozguroglu, Mustafa, additional, Santiago, Linda, additional, Saab, Rabih, additional, Li, Pao-Chen, additional, Tagliaferri, Margit Cecile, additional, Lin, Wei, additional, Tagliaferri, Mary Ann, additional, and Loriot, Yohann, additional

Published
2020
Full Text
View/download PDF

50. PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).

Author

Tannir, Nizar M., primary, Agarwal, Neeraj, additional, Pal, Sumanta K., additional, Cho, Daniel C., additional, Formiga, Maria, additional, Guo, Jun, additional, George, Daniel J., additional, Tagliaferri, Mary Ann, additional, Singel, Stina Mui, additional, O'Keeffe, Bridget A., additional, Hannah, Alison L., additional, Balbas, Minna, additional, and Penkov, Konstantin, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results